RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Status:
Recruiting
Trial end date:
2032-09-30
Target enrollment:
Participant gender:
Summary
This phase 1b study investigates the safety and feasibility of combining pre-operative
radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with
hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess
the benefits of concurrent use of these treatments in a specific participant population,
focusing on their safety and tolerability. The hypothesis is that the combination therapy
will be well-tolerated, providing valuable insights into its effectiveness for future
clinical applications.